European court rules Teva, Cephalon must pay $60M fine for reverse payment scheme after failed appeal

19 Oct 2023
endpts.com
Patent Infringement
Teva and its subsidiary Cephalon’s hopes that a European court would dismiss or reduce more than $60 million in fines have been dashed after the court ruled against it yesterday in a case that accused the companies of conspiring in a pay-for-delay scheme.
Back in 1997, Cephalon started selling its sleep disorder drug Provigil (modafinil) in the UK and then several other countries by 2005. As patents for the drug were about to expire, Cephalon created a second generation drug called Nuvigil with plans to create another called Sparlon, both based on the active ingredient modafinil.
European court rules Teva, Cephalon must pay $60M fine for reverse payment scheme after failed appeal
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.